Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

Geoffrey Falkson, J. J. Van Dyk, Errol B. van Eden et al. · Cancer · 1975 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia—Haematosarcoma and Solid Tumours

BMJ · 1973 · 89 citations · Full text

Medicine, Hematology, Pharmacology +12

Pyogenic cocci in infantile eczema throughout one year.

Ruth Smith, V. G. Alder, R. P. Warin · BMJ · 1975 · 88 citations · Full text

Life Sciences, Dermatology, Microbiology +13

Etoposide—chemistry, preclinical and clinical pharmacology

W. Achterrath, N. Niederle, R. Raettig et al. · Cancer Treatment Reviews · 1982 · 34 citations

Medicine, Medicinal Chemistry, Pharmacology +12

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

J H Edmonson, David G. Decker, George D. Malkasian et al. · Gynecologic Oncology · 1978 · 27 citations

Medicine, Oncology, Pharmacology +13